Loading
Zivo Bioscience, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by STROME MARK E, was filed 24 Apr 2026.
Zivo Bioscience, Inc.: what insiders have been doing
Zivo Bioscience, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 9 filings came from 5 insiders.
Only purchases show up on the open market, 9 purchases in all worth €584k, filed by 5 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €170k, bought by Strome Mark E and made public on 24 April 2026. Those buying include 3 senior executives, 1 major shareholder and 1 chief executive.
In all, 7 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 24 April 2026, 183 days ago. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 277 companies) published 8 filings over the same period, against 9 filings here. Since 2016, the database holds 184 purchases and 1 sale by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
215
Thresholds
n/a
Buy Volume
€8M
184 ops. · all time
Sell Volume
€296
1 ops. · all time
Who traded when
BuySaleLaith L. Yaldoo9 buys
Mark E. Strome4 buys
Christopher D. Maggiore2 buys1 sale
Alison A. Cornell1 buy
John Bernard Payne1 buy
Since the insiders bought
- +367.6%Entry US$1.39 · Close 19 Oct 2026 US$6.50
- -29.7%Entry US$9.25 · Close 19 Oct 2026 US$6.50
- -38.0%Entry US$10.49 · Close 19 Oct 2026 US$6.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$6.50
Analyst consensus
Income statement
RevenueUS$157.2k
Gross profitUS$49k31% margin
EBITDA-US$13.4M-8499% margin
Net income-US$13.4M-8513.4% margin
Valuation
Beta0.39
Balance sheet & cash
Market capUS$27.4M
Total debtUS$254.4k
Free Cash Flow-US$4.3M
Profitability & ownership
ROA-1001.9%
% insiders47.3%
% institutions0.1%
Last declaration on 24 April 2026
Declarations215 total
100,000 shares@ US$2.006.5% of flowCommon StockSEC:0001213900-26-047650:0
Canonical exit: 16 Jul 2026 (T+90)
1,543 shares@ US$9.722.5% of flowCommon StockSEC:0001654954-26-001833:0
Canonical exit: 28 May 2026 (T+90)
20,000 shares@ US$9.776.3% of flowCommon StockSEC:0001213900-26-016803:0
Canonical exit: 13 May 2026 (T+90)
2,434 shares@ US$10.274.2% of flowCommon StockSEC:0001654954-26-001157:0
Canonical exit: 11 May 2026 (T+90)
11,709 shares@ US$8.5426.8% of flowCommon StockSEC:0001654954-26-000652:0
Canonical exit: 26 Apr 2026 (T+90)
11,709 shares@ US$8.5442.9% of flowCommon StockSEC:0001654954-26-000651:0
Canonical exit: 26 Apr 2026 (T+90)
1,766 shares@ US$8.492.6% of flowCommon StockSEC:0001654954-26-000630:0
Canonical exit: 14 Apr 2026 (T+90)
1,766 shares@ US$8.491.0% of flowCommon StockSEC:0001654954-26-000631:0
Canonical exit: 14 Apr 2026 (T+90)
2,777 shares@ US$9.004.3% of flowCommon StockSEC:0001641073-25-000004:0
Canonical exit: 26 Feb 2026 (T+90)
20,259 shares@ US$12.348.3% of flowCommon StockSEC:0001213900-25-100376:0
Canonical exit: 11 Jan 2026 (T+90)
1,659 shares@ US$12.053.4% of flowCommon StockSEC:0001654954-25-011774:0
Canonical exit: 8 Jan 2026 (T+90)
23,682 shares@ US$12.0119.3% of flowCommon StockSEC:0001654954-25-011614:0
Canonical exit: 6 Jan 2026 (T+90)
15,322 shares@ US$15.9941.4% of flowCommon StockSEC:0001641073-25-000003:0
Canonical exit: 29 Dec 2025 (T+90)
3,488 shares@ US$14.338.5% of flowCommon StockSEC:0001654954-25-007028:0
Canonical exit: 11 Sept 2025 (T+90)
20 shares@ US$16.250.0% of flowCommon StockSEC:0001654954-25-004085:0
2,880 shares@ US$17.538.8% of flowCommon StockSEC:0001654954-25-003907:1
Canonical exit: 22 Apr 2025 (T+90)
7,200 shares@ US$17.52824.0% of flowCommon StockSEC:0001654954-25-003907:0
Canonical exit: 22 Apr 2025 (T+90)
34,000 shares@ US$18.5023.3% of flowCommon StockSEC:0001213900-25-004766:0
8,281 shares0Common StockSEC:0001654954-25-000101:1
5,740 shares0Common StockSEC:0001654954-25-000107:1
7,528 shares0Common StockSEC:0001654954-25-000103:1
7,277 shares0Common StockSEC:0001654954-25-000105:1
1,300 shares0Common StockSEC:0001654954-25-000105:0
1,516 shares0Common StockSEC:0001654954-25-000101:0
1,354 shares0Common StockSEC:0001654954-25-000103:0
25 of 215 declarations
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. is a United States-based research and development company listed on NASDAQ under the ticker ZIVOW. For international investors, it is best understood as a small-cap biotech/agritech platform whose core value proposition is built around proprietary freshwater algae strains and the development of natural bioactive molecules. The company’s public disclosures describe it as a Nevada corporation with operational roots in the Michigan area, including Bloomfield Hills and Keego Harbor, and its long-term strategy has centered on translating algae science into commercial products, licensing opportunities, and strategic partnerships.
Zivo’s business model is multi-layered. Its near-term focus is on nutritional compounds, food ingredients, and functional food applications derived from its proprietary algal biomass and extracts. Management has highlighted potential benefits such as supporting healthy cholesterol balance, immune function, muscle recovery, and joint health. In parallel, the company is pursuing more advanced product opportunities in human health, animal health, and pharmaceutical-oriented applications, where its bioactive molecules may be developed into nutraceutical, biologic, or medicinal candidates. A third pillar is its agtech vision: Zivo has also promoted a large-scale microalgae farm concept designed for warm-temperate and semi-tropical regions, intended to create a scalable production base for its proprietary strains and to support a broader supply chain.
Read moreShow less
From a competitive standpoint, Zivo operates in a niche where scientific validation, intellectual property, and commercialization execution matter more than scale today. The company competes indirectly with plant-based ingredient suppliers, specialty nutrition companies, algae technology developers, and early-stage biotech firms pursuing immune and inflammatory health solutions. Its potential differentiation lies in a proprietary strain portfolio, a “natural / non-GMO / sustainable” positioning, and the ability to span multiple addressable markets rather than relying on a single product category. However, the investment case remains highly execution-dependent, and the company’s commercial scale is still limited relative to established food, ingredient, and biotech peers.
Recent highlights include ongoing communication around the commercialization of proprietary algal biomass as a human food or food ingredient, continued investor-relations activity, and multiple SEC filings, including Form 4 insider transaction reporting. These disclosures underscore that ZIVOW remains a closely watched micro-cap NASDAQ name whose profile is driven by R&D milestones, regulatory filings, partnership developments, and the company’s ability to convert algae-based science into repeatable revenue streams in the United States and beyond.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
